June 2020

Cancer Killers

Fusion Pharmaceuticals Announces Pricing of Initial Public Offering.

Hamilton, Ontario and Boston.  25 June 2020.  Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pricing of its initial public offering of 12,500,000 common shares at a public offering price of $17.00 per share.  All of the shares are being offered by Fusion.  […]

Fusion Pharmaceuticals Announces Pricing of Initial Public Offering. Read More »

Alflorex

Novozymes acquires PrecisionBiotics Group.

Dublin, Ireland.  25 June 2020.  Seroba’s portfolio company, PrecisionBiotics Group has been acquired by Novozymes. Based in Cork, Ireland, PrecisionBiotics Group holds a leading position within probiotics for human gut health.  Its products include the regular award-winning Alflorex for digestive health and Zenflore for stress reduction.  Precision Biotics, which was a spin-out of UCC, has

Novozymes acquires PrecisionBiotics Group. Read More »

Innovo

New U.K. Study Offers Good News to Sufferers During World Continence Week

United Kingdom.  22 June 2020.  A new study has been published in the Journal of Medical Economics demonstrating that INNOVO® is a compelling and cost-effective treatment option for Stress Urinary Incontinence in adult females. (Authors: Ash Monga, Mehdi Javanbakht, Ph.D.) You can read details of the report here This is great news for women suffering

New U.K. Study Offers Good News to Sufferers During World Continence Week Read More »

Shorla Pharma

Shorla Pharma Closes $8.3m Series A Funding Round

Dublin and Clonmel, Ireland. June 4, 2020.   Shorla Pharma Limited (‘Shorla’), an Irish specialty pharmaceutical company has today announced the completion of a Series A investment of $8.3m.  The financing was led by Seroba Life Sciences (‘Seroba’), a European Venture Capital firm headquartered in Dublin, Ireland with additional investment from Irish and Canadian based family

Shorla Pharma Closes $8.3m Series A Funding Round Read More »

Quanta Round

Quanta provides compact dialysis systems to NHS to support increased need caused by COVID-19 pandemic

Alcester, Warwickshire, UK.  01 June 2020.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology innovation company, today announced that it has been proudly supporting the ongoing National Health Service (NHS) COVID-19 response for emergency dialysis provision by supplying its next-generation SC+ hemodialysis system to select NHS Trusts in the

Quanta provides compact dialysis systems to NHS to support increased need caused by COVID-19 pandemic Read More »

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top